S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
Log in
NASDAQ:ARNA

Arena Pharmaceuticals Stock Forecast, Price & News

$73.57
+2.06 (+2.88 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$69.02
Now: $73.57
$73.83
50-Day Range
$71.51
MA: $79.49
$83.95
52-Week Range
$32.95
Now: $73.57
$90.19
Volume616,988 shs
Average Volume516,870 shs
Market Capitalization$4.44 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.83
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, a Phase IIb/III clinical trial for Crohn's disease, and a Phase IIb clinical trial for atopic dermatitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; and APD418 that is in Phase I clinical trial for acute heart failure. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Beacon Discovery; Boehringer Ingelheim International GmbH; and Eisai Co., Ltd. and Eisai Inc. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.
Arena Pharmaceuticals logo

Headlines

Recap: Arena Pharmaceuticals Q4 Earnings
February 23, 2021 |  finance.yahoo.com
Arena Pharmaceuticals Earnings Preview
February 22, 2021 |  finance.yahoo.com
Is Arena Pharmaceuticals Stock a Good Buy?
January 6, 2021 |  stocknews.com
Is ARNA A Good Stock To Buy Now?
December 14, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ARNA
CUSIP04004710
Phone858-453-7200
Employees320
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$806.43 million
Cash Flow$7.21 per share
Book Value$21.38 per share

Profitability

Net Income$397.55 million

Miscellaneous

Market Cap$4.44 billion
Next Earnings Date5/6/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.31 out of 5 stars

Medical Sector

480th out of 1,972 stocks

Pharmaceutical Preparations Industry

231st out of 772 stocks

Analyst Opinion: 2.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
$73.57
+2.06 (+2.88 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ARNA News and Ratings via Email

Sign-up to receive the latest news and ratings for ARNA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Arena Pharmaceuticals (NASDAQ:ARNA) Frequently Asked Questions

Is Arena Pharmaceuticals a buy right now?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arena Pharmaceuticals in the last year. There are currently 15 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Arena Pharmaceuticals stock.
View analyst ratings for Arena Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Arena Pharmaceuticals?

Wall Street analysts have given Arena Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Arena Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Arena Pharmaceuticals' next earnings date?

Arena Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Arena Pharmaceuticals
.

How were Arena Pharmaceuticals' earnings last quarter?

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) issued its earnings results on Monday, February, 22nd. The biopharmaceutical company reported ($2.10) EPS for the quarter, missing the Zacks' consensus estimate of ($1.85) by $0.25. During the same period in the previous year, the company earned ($1.76) earnings per share.
View Arena Pharmaceuticals' earnings history
.

How has Arena Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

Arena Pharmaceuticals' stock was trading at $40.42 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ARNA shares have increased by 82.0% and is now trading at $73.57.
View which stocks have been most impacted by COVID-19
.

When did Arena Pharmaceuticals' stock split? How did Arena Pharmaceuticals' stock split work?

Shares of Arena Pharmaceuticals reverse split on Monday, June 19th 2017. The 1-10 reverse split was announced on Wednesday, June 14th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 16th 2017. An investor that had 100 shares of Arena Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for ARNA?

15 brokerages have issued 1 year price targets for Arena Pharmaceuticals' shares. Their forecasts range from $62.00 to $120.00. On average, they expect Arena Pharmaceuticals' stock price to reach $89.80 in the next twelve months. This suggests a possible upside of 22.1% from the stock's current price.
View analysts' price targets for Arena Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Arena Pharmaceuticals' key executives?

Arena Pharmaceuticals' management team includes the following people:
  • Mr. Amit D. Munshi M.B.A., Pres, CEO & Director (Age 53, Pay $1.23M)
  • Mr. Vincent E. Aurentz, Exec. VP & Chief Bus. Officer (Age 53, Pay $701.81k)
  • Dr. Preston S. Klassen, Advisor (Age 52, Pay $791.36k)
  • Mr. Robert Lisicki, Exec. VP & Chief Commercial Officer (Age 54, Pay $841.77k)
  • Ms. Laurie D. Stelzer, Exec. VP & CFO (Age 53)
  • Dr. Douglas A. Bakan, Exec. VP of Technical Operations
  • Megan E. Knight, Director of Investor Relations
  • Ms. Joan Schmidt, Exec. VP, Gen. Counsel & Sec. (Age 57)
  • Patrick Malloy, VP of Investor Relations & Corp. Communications
  • Ms. Suzanne C. Zoumaras, Exec. VP & Chief HR Officer (Age 57)

What is Amit Munshi's approval rating as Arena Pharmaceuticals' CEO?

16 employees have rated Arena Pharmaceuticals CEO Amit Munshi on Glassdoor.com. Amit Munshi has an approval rating of 66% among Arena Pharmaceuticals' employees.

Who are some of Arena Pharmaceuticals' key competitors?

What other stocks do shareholders of Arena Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arena Pharmaceuticals investors own include Advanced Micro Devices (AMD), (CGC), Inovio Pharmaceuticals (INO), Cytokinetics (CYTK), Micron Technology (MU), NVIDIA (NVDA), Novavax (NVAX), Alibaba Group (BABA), GW Pharmaceuticals (GWPH) and AT&T (T).

What is Arena Pharmaceuticals' stock symbol?

Arena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARNA."

Who are Arena Pharmaceuticals' major shareholders?

Arena Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (9.27%), Avoro Capital Advisors LLC (7.20%), Lord Abbett & CO. LLC (3.18%), Northern Trust Corp (1.67%), Alliancebernstein L.P. (1.67%) and Bank of New York Mellon Corp (1.55%). Company insiders that own Arena Pharmaceuticals stock include Amit Munshi, Christopher Cabell, Jayson Donald Alexander Dallas, Kevin Robert Lind, Manmeet Singh Soni, Randall E Woods, Robert Lisicki, Steven W Spector, Tina Susan Nova and Vincent Aurentz.
View institutional ownership trends for Arena Pharmaceuticals
.

Which institutional investors are selling Arena Pharmaceuticals stock?

ARNA stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Rhenman & Partners Asset Management AB, Wells Fargo & Company MN, Panagora Asset Management Inc., Dimensional Fund Advisors LP, Nuveen Asset Management LLC, Alliancebernstein L.P., and Rothschild & Co. Asset Management US Inc.. Company insiders that have sold Arena Pharmaceuticals company stock in the last year include Amit Munshi, Christopher Cabell, Jayson Donald Alexander Dallas, Manmeet Singh Soni, Robert Lisicki, Tina Susan Nova, and Vincent Aurentz.
View insider buying and selling activity for Arena Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Arena Pharmaceuticals stock?

ARNA stock was purchased by a variety of institutional investors in the last quarter, including Avoro Capital Advisors LLC, Norges Bank, Avidity Partners Management LP, SummerHaven Investment Management LLC, Viking Global Investors LP, Credit Suisse AG, Rice Hall James & Associates LLC, and Nicholas Investment Partners LP.
View insider buying and selling activity for Arena Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Arena Pharmaceuticals?

Shares of ARNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arena Pharmaceuticals' stock price today?

One share of ARNA stock can currently be purchased for approximately $73.57.

How much money does Arena Pharmaceuticals make?

Arena Pharmaceuticals has a market capitalization of $4.44 billion and generates $806.43 million in revenue each year. The biopharmaceutical company earns $397.55 million in net income (profit) each year or $7.69 on an earnings per share basis.

How many employees does Arena Pharmaceuticals have?

Arena Pharmaceuticals employs 320 workers across the globe.

What is Arena Pharmaceuticals' official website?

The official website for Arena Pharmaceuticals is www.arenapharm.com.

Where are Arena Pharmaceuticals' headquarters?

Arena Pharmaceuticals is headquartered at 6154 Nancy Ridge Drive, San Diego CA, 92121.

How can I contact Arena Pharmaceuticals?

Arena Pharmaceuticals' mailing address is 6154 Nancy Ridge Drive, San Diego CA, 92121. The biopharmaceutical company can be reached via phone at 858-453-7200 or via email at [email protected]


This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.